Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to doravirine/islatravir versus continued bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed adults with HIV-1
2019-000587-23Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing Switch to doravirine/islatravir with Continue bictegravir/emtricitabine/tenofovir alafenamide (2 arms). Started Nov 2019; status: completed.
02
Drugs
doravirineislatravirbictegraviremtricitabinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2019-000587-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000587-23.